Wapapapow
2021-01-24
Yes wow
Gilead (GILD) Up 19% in the Past Month: What Lies Ahead?
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":319912782,"tweetId":"319912782","gmtCreate":1611471320846,"gmtModify":1703750548235,"author":{"id":3556787208739110,"idStr":"3556787208739110","authorId":3556787208739110,"authorIdStr":"3556787208739110","name":"Wapapapow","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Yes wow</p></body></html>","htmlText":"<html><head></head><body><p>Yes wow</p></body></html>","text":"Yes wow","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/319912782","repostId":2105459536,"repostType":4,"repost":{"id":"2105459536","kind":"news","pubTimestamp":1611300933,"share":"https://www.laohu8.com/m/news/2105459536?lang=&edition=full","pubTime":"2021-01-22 15:35","market":"us","language":"en","title":"Gilead (GILD) Up 19% in the Past Month: What Lies Ahead?","url":"https://stock-news.laohu8.com/highlight/detail?id=2105459536","media":"Zacks","summary":"Shares ofGilead Sciences, Inc. are up 19.3% in the past month. The company, had an eventful 2020 and","content":"<p>Shares of<b>Gilead Sciences, Inc</b>. are up 19.3% in the past month. The company, had an eventful 2020 and was in the spotlight due to its coronavirus treatment, Veklury (remdesivir). The FDA granted full approval to Veklury for the treatment of patients with COVID-19 and the European Commission (“EC”) also granted conditional Marketing Authorization for the same.</p>\n<p>The stock has gained 7.2% in the past year compared with theindustry’s growth of 13.9%.</p>\n<p><img src=\"https://static.tigerbbs.com/af3ba6e3f673d6fd0f236d1fd5a528aa\" tg-width=\"620\" tg-height=\"283\"></p>\n<p>Last week, the companyincreasedits annual sales guidance for 2020 as the worsening of the coronavirus pandemic drove sales for Veklury. Total product sales are now projected to be $24.3-$24.35 billion for 2020, up from the previous guidance of $23-$23.5 billion. Veklury sales witnessed growth as hospitalization and treatment rates were higher than expected, given the most recent COVID-19 surge. Veklury sales are estimated at $2.8-$2.825 billion.</p>\n<p>Total product sales, excluding Veklury, are projected to be $21.5-$21.525 billion, considering the underlying strong Biktarvy uptake, partially offset by the loss of exclusivity of Truvada in the United States and the impact of COVID-19 primarily on Gilead’s pre-exposure prophylaxis (“PrEP”) franchise and chronic hepatitis C virus (“HCV”) franchise.</p>\n<p>While Veklury sales were strong as the pandemic worsened in the last couple of months, the rollout of vaccines from<b>Pfizer</b> and others might lead to a decline in sales eventually.</p>\n<p>Nevertheless, Gilead is likely to maintain momentum on its strong HIV franchise led by Biktarvy despite stiff competition from the likes of<b>Glaxo</b>. The label expansion of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) as a prevention option has boosted sales of the treatment. The FDA had earlier also extended the indication for Truvada as PrEP to include at-risk adolescents. Approval of new therapies has strengthened the franchise.</p>\n<p>We remind investors that the massive decline in sales of its once lucrative HCV franchise has prompted it to focus on the HIV franchise, Yescarta and other newer avenues.</p>\n<p>Gilead is diversifying into the oncology space. To that end, it acquired Immunomedics for approximately $21 billion and entered into strategic collaborations to foray into the lucrative oncology space. In April 2020, Gilead acquired Forty Seven for $4.9 billion and gained magrolimab, an investigational monoclonal antibody in clinical development for the treatment of a number of hematological cancers. Gilead also acquired a 49.9% equity interest in Pionyr Immunotherapeutics, Inc., a privately-held company pursuing novel biology in the field of immuno-oncology.</p>\n<p>It has also collaborated with<b>Novo Nordisk</b> for developing treatments for non-alcoholic steatohepatitis (NASH).</p>\n<p><b>Biggest Tech Breakthrough in a Generation</b></p>\n<p>Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.</p>\n<p>A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead (GILD) Up 19% in the Past Month: What Lies Ahead?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead (GILD) Up 19% in the Past Month: What Lies Ahead?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-01-22 15:35 GMT+8 <a href=https://www.zacks.com/stock/news/1250053/gilead-gild-up-19-in-the-past-month-what-lies-ahead><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares ofGilead Sciences, Inc. are up 19.3% in the past month. The company, had an eventful 2020 and was in the spotlight due to its coronavirus treatment, Veklury (remdesivir). The FDA granted full ...</p>\n\n<a href=\"https://www.zacks.com/stock/news/1250053/gilead-gild-up-19-in-the-past-month-what-lies-ahead\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://www.zacks.com/stock/news/1250053/gilead-gild-up-19-in-the-past-month-what-lies-ahead","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2105459536","content_text":"Shares ofGilead Sciences, Inc. are up 19.3% in the past month. The company, had an eventful 2020 and was in the spotlight due to its coronavirus treatment, Veklury (remdesivir). The FDA granted full approval to Veklury for the treatment of patients with COVID-19 and the European Commission (“EC”) also granted conditional Marketing Authorization for the same.\nThe stock has gained 7.2% in the past year compared with theindustry’s growth of 13.9%.\n\nLast week, the companyincreasedits annual sales guidance for 2020 as the worsening of the coronavirus pandemic drove sales for Veklury. Total product sales are now projected to be $24.3-$24.35 billion for 2020, up from the previous guidance of $23-$23.5 billion. Veklury sales witnessed growth as hospitalization and treatment rates were higher than expected, given the most recent COVID-19 surge. Veklury sales are estimated at $2.8-$2.825 billion.\nTotal product sales, excluding Veklury, are projected to be $21.5-$21.525 billion, considering the underlying strong Biktarvy uptake, partially offset by the loss of exclusivity of Truvada in the United States and the impact of COVID-19 primarily on Gilead’s pre-exposure prophylaxis (“PrEP”) franchise and chronic hepatitis C virus (“HCV”) franchise.\nWhile Veklury sales were strong as the pandemic worsened in the last couple of months, the rollout of vaccines fromPfizer and others might lead to a decline in sales eventually.\nNevertheless, Gilead is likely to maintain momentum on its strong HIV franchise led by Biktarvy despite stiff competition from the likes ofGlaxo. The label expansion of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) as a prevention option has boosted sales of the treatment. The FDA had earlier also extended the indication for Truvada as PrEP to include at-risk adolescents. Approval of new therapies has strengthened the franchise.\nWe remind investors that the massive decline in sales of its once lucrative HCV franchise has prompted it to focus on the HIV franchise, Yescarta and other newer avenues.\nGilead is diversifying into the oncology space. To that end, it acquired Immunomedics for approximately $21 billion and entered into strategic collaborations to foray into the lucrative oncology space. In April 2020, Gilead acquired Forty Seven for $4.9 billion and gained magrolimab, an investigational monoclonal antibody in clinical development for the treatment of a number of hematological cancers. Gilead also acquired a 49.9% equity interest in Pionyr Immunotherapeutics, Inc., a privately-held company pursuing novel biology in the field of immuno-oncology.\nIt has also collaborated withNovo Nordisk for developing treatments for non-alcoholic steatohepatitis (NASH).\nBiggest Tech Breakthrough in a Generation\nBe among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.\nA select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s.","news_type":1},"isVote":1,"tweetType":1,"viewCount":251,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/319912782"}
精彩评论